{
    "Trade/Device Name(s)": [
        "EliA SmDP-S"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K202067",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132631"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LKP"
    ],
    "Summary Letter Date": "July 14, 2021",
    "Summary Letter Received Date": "December 1, 2020",
    "Submission Date": "November 30, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgG antibodies to Sm (Smith) protein D component"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 250",
        "E-module of Phadia 2500",
        "Phadia 5000 series"
    ],
    "Method(s)/Technology(ies)": [
        "Solid-phase fluoroimmunoassay"
    ],
    "Methodologies": [
        "Semi-quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Control",
        "Calibrator",
        "System",
        "Platform",
        "Automated system"
    ],
    "Document Summary": "FDA 510(k) summary for EliA SmDP-S semi-quantitative fluoroimmunoassay for IgG antibodies to Sm protein D, aiding diagnosis of SLE.",
    "Indications for Use Summary": "Intended for in vitro semi-quantitative measurement of IgG antibodies to Sm in human serum and EDTA-plasma as an aid in diagnosing systemic lupus erythematosus (SLE), in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}